Negotiation Outcomes Calculator
Our interactive model lets you control Medicare prescription drug price negotiation policy. Select policy options and see the effects and tradeoffs between the number of drugs that would be subject to negotiation and the potential savings to Medicare for 2026-2030.
Policy Outcomes
This model estimates the effect of negotiation based on current law and compares it with potential changes to policy. Estimated impacts of proposed policy changes compared to existing Medicare policy for 2026-2030.
Comparing:
FAQs
The data in this article comes from a census data set provided by this link. Lorem ipsum dolor sit amet consectetur. Odio eget senectus eu nibh sit amet risus elementum non. Eleifend semper sit mi enim lacus turpis. Tincidunt in nulla placerat integer erat neque nibh donec mauris. Arcu magna scelerisque risus cursus nunc scelerisque.
Additional Credits
Kari Benson, MA, is the Deputy Assistant Secretary for Aging; Kelly Cronin, MS, is the Deputy Administrator for Innovation and Partnership; Vicki Gottlich, JD, is the Deputy Administrator for Policy and Evaluation; and Jennifer Baker, MPH, is an advisor, all at the Administration for Community Living. Amy Herr, MHS, is director of Health Policy at West Health and a member of ASA’s Board of Directors and its Executive Committee. Rani Snyder, MPA, is vice president, Program and a member of ASA’s Board of Directors and its Executive Committee, and Scott Bane, JD, MPA, is senior program officer, both at The John A. Hartford Foundation. Narda Ipakchi, MBA, is vice president of Policy, and Erin Westphal, MS, is a program officer, both at The SCAN Foundation.